TEC24-Hematology and Gene Therapy Research Group: HemaTerGe

The overall objective of HemaTerGe is to deepen the biological and clinical knowledge of haematological diseases in order to improve their prognosis and generate efficient, safe and cost-effective advanced therapy medicines (ATMP) for the treatment of haematological diseases, cancer and monogenetic diseases. This objective requires collaboration and coordination between scientists, physicians and other stakeholders (pharmaceutical companies, regulators, patients, etc.) to provide regulatory preclinical data and facilitate their application to the national health system. In particular, the new HemaTerGe group seeks to advance the treatment of haematological diseases, with a special focus on cancer and monogenetic diseases. To this end, the group has basic researchers who are experts in gene therapy and genome editing and clinical researchers with extensive experience in research into different haematological diseases and in conducting clinical trials.